Education
About Us
Working with TipRanks
Follow Us
IQVIA Holdings Inc (IQV)
NYSE:IQV
IQV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$176.03 - $253.84
Previous CloseN/A
Volume300.39K
Average Volume (3M)1.55M
Market Cap
$31.28B
Enterprise Value$48.17B
Total Cash (Recent Filing)$1.70B
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)23.7
Beta1.05
Next Earnings
Apr 30, 2025EPS Estimate
2.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.50
Shares Outstanding176,315,030
10 Day Avg. Volume1,564,656
30 Day Avg. Volume1,545,484
Financial Highlights & Ratios
PEG Ratio9.60
Price to Book (P/B)N/A
Price to Sales (P/S)2.12
Price to Cash Flow (P/CF)9.30
P/FCF Ratio8.00
Enterprise Value/Market Cap1.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.96
Enterprise Value/Ebitda14.17
Forecast
1Y Price Target
$244.50Price Target Upside37.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
IQVIA Holdings News
PremiumCompany Announcements
IQVIA Holdings: Strong Earnings Amid Challenges
PremiumCompany Announcements
IQVIA Holdings Reports Robust 2024 Earnings
---
Bulls Say, Bears Say
Bulls Say
Business StrategyIQV's initiatives to incorporate AI to enhance all aspects of its operations and products have shown positive results, winning contracts with customers.
EarningsIQVIA reported a top- and bottom-line beat with revenue above the Street estimate, driven by better-than-expected TAS revenue.
Financial PerformanceThe company's free cash flow was solid, with a full-year increase of 41% year over year.
Bears Say
BookingsThe higher level of cancellations, of almost $1B, and what appears to be another quarter of a y/y decline in bookings, is worrisome.
Market ConditionsStill-elevated cancellation rates are further evidence that the expected recovery in clinical trial demand is not going to be linear.
Revenue GrowthRDS revenue growth is expected to be flat in the first half due to elevated cancellations, indicating short-term challenges.
---
Ownership Overview
0.85% Insiders
23.80% Mutual Funds
25.61% Other Institutional Investors
25.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IQV FAQ
What was IQVIA Holdings Inc’s price range in the past 12 months?
IQVIA Holdings Inc lowest stock price was $176.03 and its highest was $253.84 in the past 12 months.
What is IQVIA Holdings Inc’s market cap?
IQVIA Holdings Inc’s market cap is $31.28B.
When is IQVIA Holdings Inc’s upcoming earnings report date?
IQVIA Holdings Inc’s upcoming earnings report date is Apr 30, 2025 which is in 30 days.
How were IQVIA Holdings Inc’s earnings last quarter?
IQVIA Holdings Inc released its earnings results on Feb 06, 2025. The company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $3.109 by $0.011.
Is IQVIA Holdings Inc overvalued?
According to Wall Street analysts IQVIA Holdings Inc’s price is currently Undervalued.
Does IQVIA Holdings Inc pay dividends?
IQVIA Holdings Inc does not currently pay dividends.
What is IQVIA Holdings Inc’s EPS estimate?
IQVIA Holdings Inc’s EPS estimate is 2.64.
How many shares outstanding does IQVIA Holdings Inc have?
IQVIA Holdings Inc has 176,315,030 shares outstanding.
What happened to IQVIA Holdings Inc’s price movement after its last earnings report?
IQVIA Holdings Inc reported an EPS of $3.12 in its last earnings report, beating expectations of $3.109. Following the earnings report the stock price went up 2.2%.
Which hedge fund is a major shareholder of IQVIA Holdings Inc?
Currently, no hedge funds are holding shares in IQV
---
IQVIA Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$244.50 (37.83% Upside)
$244.50 (37.83% Upside)
Blogger Sentiment
Bullish
IQV Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 462.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $255.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 10.0%
Last 30 Days ▼ 10.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.85%
12-Months-Change
Fundamentals
Return on Equity
22.55%
Trailing 12-Months
Asset Growth
0.82%
Trailing 12-Months
Company Description
IQVIA Holdings Inc
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
---
IQV Company Deck
---
IQV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
IQVIA delivered strong results in 2024, with notable achievements in revenue and strategic partnerships, alongside advancements in AI and global health initiatives. However, the significant cancellations and challenging macroeconomic conditions posed considerable hurdles. The outlook remains cautiously optimistic with expected volatility in some segments.Read More>---
IQV Revenue Breakdown
55.35% Research & Development Solutions
39.99% Technology & Analytics Solutions
4.66% Contract Sales & Medical Solutions
---
IQV Stock 12 Month Forecast
Average Price Target
$244.50
▲(37.83% Upside)
Technical Analysis
Baxter International
―
Cardinal Health
―
Labcorp Holdings
―
McKesson
―
Quest Diagnostics
―
Best Analysts Covering IQV
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+11.58%
upgraded a buy rating 4 months ago
Copying Jack Meehan's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +11.58% per trade.
---